Redefining Non-small Cell Lung Cancer: The Role of Histology

History of Therapy in Advanced NSCLC: FDA Approval Dates

ECOG 1594: What Did It Teach Us?

Bevacizumab in NSCLC: Key Clinical Outcomes

Grade 3-5 Non-hematologic Toxicity Associated With

Bevacizumab

AVAIL Study Design

AVAIL: Progression-Free Survival

Study Design: Cisplatin/Pemetrexed

vs Cisplatin/Gemcitabine in First-line NSCLC

Cisplatin/Gemcitabine vs Cisplatin/Pemetrexed

in Advanced NSCLC

Toxicities Associated With Platinum-Based Combination

Chemotherapy in Advanced NSCLC

Phase 3 PointBreak Study Design

PointBreak: Overall Survival From Randomization (Intent-to-

Treat)

PointBreak: Prespecified Exploratory Analysis of KM OS from Randomization: Maintenance

Group

PointBreak: CTCAEs (Version 3) Possibly Related to Study Drug in Safety

Population